TOVX Theriva Biologics, Inc.

NYSE therivabio.com


$ 0.24 $ -0.03 (-12.5 %)    

Monday, 17-Nov-2025 15:42:00 EST
QQQ $ 602.34 $ -5.20 (-0.85 %)
DIA $ 466.18 $ -5.48 (-1.16 %)
SPY $ 664.83 $ -6.26 (-0.93 %)
TLT $ 89.11 $ 0.22 (0.25 %)
GLD $ 370.86 $ -4.31 (-1.15 %)
$ 0.2374
$ 0.27
$ 0.24 x 1,380
$ 0.24 x 4,344
$ 0.23 - $ 0.27
$ 0.23 - $ 2.08
3,239,302
na
8.01M
$ 1.49
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-12-2025 09-30-2025 10-Q
2 08-11-2025 06-30-2025 10-Q
3 05-14-2025 03-31-2025 10-Q
4 03-06-2025 01-01-1970 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-13-2024 06-30-2024 10-Q
7 05-07-2024 03-31-2024 10-Q
8 03-25-2024 12-31-2023 10-K
9 11-13-2023 09-30-2023 10-Q
10 08-08-2023 06-30-2023 10-Q
11 05-11-2023 03-31-2023 10-Q
12 03-30-2023 12-31-2022 10-K
13 11-10-2022 09-30-2022 10-Q
14 08-11-2022 06-30-2022 10-Q
15 05-16-2022 03-31-2022 10-Q
16 03-16-2022 12-31-2021 10-K
17 11-03-2021 09-30-2021 10-Q
18 08-05-2021 06-30-2021 10-Q
19 05-05-2021 03-31-2021 10-Q
20 03-04-2021 12-31-2020 10-K
21 11-10-2020 09-30-2020 10-Q
22 08-06-2020 06-30-2020 10-Q
23 05-05-2020 03-31-2020 10-Q
24 02-20-2020 12-31-2019 10-K
25 11-04-2019 09-30-2019 10-Q
26 08-08-2019 06-30-2019 10-Q
27 05-08-2019 03-31-2019 10-Q
28 02-27-2019 12-31-2018 10-K
29 11-08-2018 09-30-2018 10-Q
30 08-08-2018 06-30-2018 10-Q
31 05-08-2018 03-31-2018 10-Q
32 02-22-2018 12-31-2017 10-K
33 11-01-2017 09-30-2017 10-Q
34 08-03-2017 06-30-2017 10-Q
35 05-04-2017 03-31-2017 10-Q
36 03-02-2017 12-31-2016 10-K
37 11-01-2016 09-30-2016 10-Q
38 08-03-2016 06-30-2016 10-Q
39 05-05-2016 03-31-2016 10-Q
40 03-10-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 theriva-biologics-q3-eps-045-beats-113-estimate

Theriva Biologics (AMEX:TOVX) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(1.1...

 theriva-biologics-addresses-unusual-nyse-trading-activity-confirms-no-new-developments-since-virage-trial-data-presentation-at-esmo-2025

Theriva™ Biologics (NYSE:TOVX), ("Theriva" or the "Company"), a diversified clinical-stage company developing t...

 theriva-biologics-secures-4m-via-immediate-exercise-of-736m-warrants-at-054share-offers-investors-1472m-new-warrants-at-same-price

Theriva™ Biologics (NYSE:TOVX), ("Theriva" or the "Company"), a diversified clinical-stage company developing t...

 theriva-biologics-to-present-vcn-12-and-vcn-01-preclinical-data-at-esgct-highlighting-novel-antitumor-mechanism-and-intracranial-feasibility-for-brain-tumors

- Preclinical data for VCN-12, the next candidate from Theriva's VCN-X discovery program, highlight a novel mechanism of ac...

 stock-market-today-nasdaq-sp-500-futures-gain-on-3rd-day-of-government-shutdownrumble-riggeti-kodiak-in-focus-updated

U.S. stock futures advanced on Friday following Thursday's record advances. Futures of major benchmark indices were higher.

 rumble-xcel-brands-and-3-stocks-to-watch-heading-into-friday

US stock futures up, Actelis Networks, XCel Brands, Rumble Inc. up after hours. Theriva Biologics to cut workforce, Open Text t...

 theriva-biologics-cuts-32-of-workforce-in-restructuring-to-focus-on-cancer-drug-development-and-regulatory-strategy-expects-will-extend-its-cash-runway-into-q2-of-2026

Item 2.05 Costs Associated with Exit or Disposal Activities. On September 28, 2025, the Board of Directors of Theriva Biologics...

 theriva-biologics-has-received-a-notice-of-allowance-for-a-us-patent-titled-alkaline-phosphatase--formulations-for-the-treatment-of-microbiome-related-diseases

https://patentcenter.uspto.gov/applications/18744950/ifw/docs

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION